Top 3 Emerging Trends Impacting the Global Tinea Pedis Treatment Market from 2017-2021: Technavio

LONDON–(BUSINESS WIRE)–#RareDiseases–Technavio’s latest report on the global
tinea pedis treatment market
provides an analysis of the
most important trends expected to impact the market outlook from
2017-2021. Technavio
defines an emerging trend as a factor that has the potential to
significantly impact the market and contribute to its growth or decline.


The research study by Technavio on the global
tinea pedis treatment market
for 2017-2021 provides a detailed
industry analysis based on the route of administration (oral and
topical), disease type (interdigital tinea pedis and vesicular tinea
pedis), and geography (the Americas, EMEA, and APAC).

 
Tinea pedis is caused by a dermatophyte foot fungus which thrives
in warm, humid conditions and is most common among young adult men.
It is a dermatophyte infection of the soles of the feet and the
interdigital spaces. Technavio analysts forecast the global tinea
pedis treatment market to grow to USD 994.25 million by 2021, at a
CAGR of more than 3% over the forecast period.
 

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2
Technavio reports and get the third for free.

The top three emerging trends driving the global tinea pedis treatment
market according to Technavio healthcare
and life sciences
research analysts are:

  • Increased funding for antifungal research
  • Increased focus on combination therapies
  • Advent of novel therapies

Increased funding for antifungal research

The growing cases of infectious diseases such as bacterial infection,
fungal infection, and viral infection are encouraging vendors in the
market to enhance their R&D efforts in this therapy area. As drug
development is a cost-intensive process, various government and
non-governmental institutes are providing financial assistance in the
development of antifungal drugs.

Institutions such as Generating Antibiotics Incentives Now and
Qualified Infectious Disease Product are providing funding for the
development of novel antifungal drugs. Such funding encourages the
research institutes and companies to invest more in antifungal drug
research, leading to market growth
,”
says Sapna Jha, a lead
analyst at Technavio for infectious
and rare diseases
research.

Increased focus on combination therapies

A current trend in the global tinea pedis treatment market is the use of
combination therapies for treating foot related fungal infections. It is
observed that a combination of systemic and topical treatment increases
the chances of removing the fungus when compared with single therapies.

For instance, the combination of oral terbinafine with topical
terbinafine and 10% urea ointment has proven to be the most successful
method of treating tinea pedis. Often, the combination of topical and
systemic therapies and surgery is used in treatment. Also,
non-pharmacological approaches such as laser treatment or mechanical
treatment are used in combination with topical and systemic therapy.

Advent of novel therapies

The global tinea pedis treatment market lacks effective and approved
drugs that can eliminate side effects related to foot fungal infections.
The absence of an effective treatment for onychomycosis, a fungal
infection that involves the nail matrix, nail bed, and nail plate can
hinder the market. The limited availability of current therapies coupled
with large patient pool can provide significant opportunities for
vendors to discover new drugs for the market.

For instance, Viamet Pharmaceuticals’ VT-1161 is a novel oral
agent formulated for the treatment of onychomycosis. The drug is
currently in phase II and has shown high potency in in vitro studies.
The approval for new drugs will overcome the side effects that limit the
use of current antifungals such as terbinafine and fluconazole
,”
says
Sapna.

Browse Related Reports:

Become a Technavio
Insights member
and access all three of these reports for a
fraction of their original cost. As a Technavio Insights member, you
will have immediate access to new reports as they’re published in
addition to all 6,000+ existing reports covering segments like
oncology,
vaccines,
and
urology
devices
. This subscription nets you thousands in savings,
while staying connected to Technavio’s constant transforming research
library, helping you make informed business decisions more efficiently.

About Technavio

Technavio
is a leading global technology research and advisory company. The
company develops over 2000 pieces of research every year, covering more
than 500 technologies across 80 countries. Technavio has about 300
analysts globally who specialize in customized consulting and business
research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research
techniques to ascertain the size and vendor landscape in a range of
markets. Analysts obtain information using a combination of bottom-up
and top-down approaches, besides using in-house market modeling tools
and proprietary databases. They corroborate this data with the data
obtained from various market participants and stakeholders across the
value chain, including vendors, service providers, distributors,
resellers, and end-users.

If you are interested in more information, please contact our media team
at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 630 333 9501
UK: +44 208 123 1770
www.technavio.com